Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 625-647

  Calvo, Ezequiel ^a   Luu The, Van ^a   Belleau, Pascal ^a   Martel, Céline ^a,b   Labrie, Fernand ^a,b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b EndoCeutics Inc   (Canada)

^c AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

Author keywords

Acolbifene; Genomic profile; Mammary gland

Indexed keywords

ACOLBIFENE; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SEQUENCE; HORMONE INHIBITION; MAMMARY GLAND; MOLECULAR PROBE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR VASCULARIZATION; UNINDEXED SEQUENCE; UPREGULATION; VALIDATION PROCESS;

ANIMALS; CLUSTER ANALYSIS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; GENES; GENES, NEOPLASM; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; PIPERIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84868192099     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2104-7     Document Type: Article

References (101)

1. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29:510-518
2. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA (2009) Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 284:17914-17925
3. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, Van Der Wees J, Lindeman GJ, Visvader JE (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9:201-209. doi:10.1038/ncb1530
4. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE (2011) Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 31:4609-4622. doi:10.1128/MCB.05766-11
5. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284
6. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10:6789-6795
7. Bitton-Worms K, Pikarsky E, Aronheim A (2010) The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer 9:54
8. Bohn OL, Nasir I, Brufsky A, Tseng GC, Bhargava R, MacM-anus K, Chivukula M (2009) Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol 3:139-146
9. Bottner M, Suter-Crazzolara C, Schober A, Unsicker K (1999) Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 297:103-110
10. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
11. Canney PA, Griffiths T, Latief TN, Priestman TJ (1987) Clinical significance of Tamoxifen withdrawal response. Lancet 1:36
12. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33-43. doi:10.1016/j.cell.2005.05.008
13. Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI, Martins R, Zeitlin E, Lamb CA, Lanari C (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res 71:3720-3731
14. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP (2007) Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyperand hypomethylated targets. Mol Cancer Ther 6:1089-1098
15. Chou J, Provot S, Werb Z (2010) GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol 222:42-49. doi:10.1002/jcp. 21943
16. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, Weisz A (2010) Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 176:2113-2130. doi:10.2353/ajpath.2010.090837
17. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect ofraloxifene on riskofbreast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197
18. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6:322-329
19. De Friend DJ, Anderson E, Bell J, Wilks DP, West CM, Mansel RE, Howell A (1994) Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 70:204-211
20. Eaton SB, Strassman BI, Nesse RM, Neel JV, Ewald PW, Williams GC, Weder AB, Eaton SB 3rd, Lindeberg S, Konner MJ, Mysterud I, Cordain L (2002) Evolutionary health promotion. Prev Med 34:109-118. doi:10.1006/pmed.2001.0876
21. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas P, Zanchetta J, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, Investigators ftMOoREM (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene (Results from a 3-year randomized clinical trial). JAMA 282:637-645
22. Fabian CJ, Kimler BF (2005) Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 23:1644-1655
23. Fisher B, Costantino JP, Lawrence Wickerham D, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90:1371-1388
24. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F (1997) (S) - (+)-4-[7-(2, 2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl] -2H-1-benzopyran-3-yl]-phenyl 2, 2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 40:2117-2122
25. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315
26. Gottardis MM, Jordan VC (1988) Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after longterm antiestrogen administration. Cancer Res 48:5183-5187
27. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C (2002) Comparison of the effects of EM-652 (SCH 57068), Tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and Raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 99:273-278
28. Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drugresistant breast cancer (MCF-7) cells. Oncogene 25:3049-3058
29. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A (2002) Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068). Menopause 9:430-435
30. Hoogstraten B, Gad El Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 54:2248-2256
31. Howell A, Dodwell DJ, Anderson H, Redford J (1992) Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617
32. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK et al (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21
33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264
34. Jagannathan V, Robinson-Rechavi M (2011) Meta-analysis of estrogen response in MCF-7 distinguishes early target genes involved in signaling and cell proliferation from later target genes involved in cell cycle and DNA repair. BMC Syst Biol 5:138. doi:10.1186/1752-0509-5-138
35. Janes KA (2011) RUNX1 and its understudied role in breast cancer. Cell Cycle 10:3461-3465. doi:10.4161/cc.10.20.18029
36. Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol 84:469-478
37. Kendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN (2005) On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA 102:4252-4257. doi:10.1073/pnas.0500607102
38. Kiguchi K, Giometti C, Chubb CH, Fujiki H, Huberman E (1992) Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Biochem Biophys Res Commun 189:1261-1267
39. Kim CH, Park JY, Lee KU, Kim JH, Kim HK (2009) Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 25:64-69
40. Kim KK, Lee JJ, Yang Y, You KH, Lee JH (2008) Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704-712
41. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, Yagi R, Sukzuki W, Tamauchi H, Hozumi K, Habu S, Kubo M, Satake M (2003) The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med 198:51-61. doi:10.1084/jem.20021200
42. Koptyra M, Gupta S, Talati P, Nevalainen MT (2011) Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol 43:1417-1421
43. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K (2011) Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS ONE 6:e20701
44. Kuroso K, Imai Y, Kobayashi M, Yanagimoto K, Suzuki T, Kojima M, Ueda Y (2010) Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 77:231-240
45. Labrie F (2008) Combination of breast cancer prevention with tissue-targeted hormone replacement therapy. In: Pasqualini JR (ed) Breast cancer: prognosis, treatment, and prevention, 2nd edn. Taylor & Francis, New York, pp 201-252
46. Labrie F (2007) Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 3:584-593
47. Labrie F (2002) Endocrine-sensitive cancers of the prostate and breast. In: Baxter J, Melmed S, New MI (eds) Genetics in Endocrinology. Lippincott-William and Wilkins, Philadelphia, pp 607-661
48. Labrie F (1995) Endocrine therapy of prostate cancer: optimal form and timing. J Clin Endocrinol Metab 80:1066-1071
49. Labrie F, Champagne P, Labrie C, Bélanger A, Roy J, Laverdière J, Deschênes L, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B (2004) Activity and safety of the orally active pure antiestrogen EM-800 (SCH 57050) in Tamoxifen-resistant breast cancer. J Clin Oncol 22:864-871
50. Labrie F, El-Alfy M, Berger L, Labrie C, Martel C, Bélanger A, Candas B, Pelletier G (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 144:4700-4706
51. Labrie F, Labrie C, Bélanger A, Giguère V, Simard J, Mérand Y, Gauthier S, Luu-The V, Candas B, Martel C, Luo S (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. In: Scolnick EM (ed) Advances in protein chemistry: drug discovery and design. Academic Press, San Diego, pp 293-368
52. Labrie F, Labrie C, Bélanger A, Simard J (2002) Third and fourth generation SERMs. In: Manni A, Verderame M (eds) Selective estrogen receptor modulators: research and clinical applications. Humana Press Inc., Totowa, pp 167-187
53. Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguère V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 69:51-84
54. Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 79:213-225
55. Lacerda L, Pusztai L, Woodward WA (2010) The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 13:99-108
56. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V (2005) From the Cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 102:11651-11656
57. Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M (2006) Jun. and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 27:345-352
58. Lemieux C, Gelinas Y, Lalonde J, Labrie F, Cianflone K, Deshaies Y (2005) Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors. J Lipid Res 46:1285-1294
59. Lemieux C, Gelinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y (2006) Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia. Metabolism 55:605-613
60. Lemieux C, Gelinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y (2005) The selective estrogen receptor modulator acolbifene reduces cholesterolemia independently of its anorectic action in control and cholesterol-fed rats. J Nutr 135:2225-2229
61. Lemieux C, Phaneuf D, Labrie F, Giguere V, Richard D, Deshaies Y (2005) Estrogen receptor alpha-mediated adipositylowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes Relat Metab Disord 29:1236-1244
62. Lemieux C, Picard F, Labrie F, Richard D, Deshaies Y (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet-and ovariectomy-induced obesity. Obes Res 11:477-490
63. Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA (2010) EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA 107:1408-1413
64. Luo S, Labrie C, Labrie F (1998) Prevention of development of dimenthylbenz (a) anthracene (DMBA)-induced mammary carcinoma in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res Treat 49:1-11
65. Luo S, Sourla A, Labrie C, Bélanger A, Labrie F (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz (a) anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology 138:4435-4444
66. Luo S, Stojanovic M, Labrie C, Labrie F (1997) Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats. Int J Cancer 73:580-586
67. Luu-The V, Paquet N, Calvo E, Cumps J (2005) Improved realtime RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques 38:287-293
68. Lykkesfeldt AE, Sorensen EK (1992) Effect of estrogens and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and tamoxifen resistant variant subline. AL 1. Acta Oncol 31:131-138
69. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY (2012) Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation. Blood. doi:10.1182/blood- 2011-06-363960
70. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459-2470
71. Martel C, Picard S, Richard V, Bélanger A, Labrie C, Labrie F (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol 74:45-56
72. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761
73. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S (2012) FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 131:881-890
74. Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger AM, Janicke F, Loning T (2008) Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treat 107(3):337-347
75. Mimeault M, Batra SK (2010) Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 224:626-635
76. Osborne CK, Coronado Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750
77. Park YJ, Lee H, Lee JH (2010) Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep 43:91-96
78. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H (2011) Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 29:2448-2458
79. Picard F, Deshaies Y, Lalonde J, Samson P, Labrie C, Bélanger A, Labrie F, Richard D (2000) Effects of the estrogen antagonist EM-652. HCl on energy balance and lipid metabolism in ovariectomized rats. Int J Obes Relat Metab Disord 24:830-840
80. Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F (1989) Antiestrogenic properties of Keoxifene trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 14:65-76
81. Pritchard KI, Thomson DB, Myers RE, Sutherland DJ, Mobbs BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787-796
82. Punyadeera C, Kamps R, Defrere S, Dijcks F, De Goeij A, Ederveen A, Dunselman G, Groothuis P (2008) Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre-and postmenopausal human endometrium. J Steroid Biochem Mol Biol 112:102-109. doi:10.1016/j.jsbmb.2008. 09.002 S0960-0760 (08) 00224-0[pii]
83. Reichenstein M, Rauner G, Barash I (2011) Conditional repression of STAT5 expression during lactation reveals its exclusive roles in mammary gland morphology, milk-protein gene expression, and neonate growth. Mol Reprod Dev 78:585-596
84. Roy J, Couillard S, Gutman M, Labrie F (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat 81:223-229
85. Sanges R, Cordero F, Calogero RA (2007) oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 23:3406-3408
86. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
87. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogeninduced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 73:104-112
88. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Mérand Y, Bélanger A, Labrie C, Labrie F (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 57:3494-3497
89. Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR (2002) Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 143:2052-2061
90. Strauss BL, Bratthauer GL, Tavassoli FA (2006) STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum Pathol 37:586-592
91. Tatchum-Talom R, Martel C, Labrie F, Marette A (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res 57:535-543
92. Thompson PA, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH (2010) Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res (Phila) 3:101-107
93. Ting AY, Blacklock AD, Smith PG (2004) Estrogen regulates vaginal sensory and autonomic nerve density in the rat. Biol Reprod 71:1397-1404. doi:10.1095/biolreprod.104.030023
94. Tomlinson D, Knowles M, Speirs V (2012) Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 130(12):2857-2866
95. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741
96. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M (2000) Comparison of human adult and fetal expression and identification of 535 housekeeping/ maintenance genes. Physiol Genomics 2:143-147
97. Wiebe VJ, Osborne CK, Fuqua SA, De Gregorio MW (1993) Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 14:173-188
98. Williamson EA, Wolf I, O'Kelly J, Bose S, Tanosaki S, Koeffler HP (2006) BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27 (Kip1). Oncogene 25:1391-1399
99. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100:2028-2033
100. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, Goodglick L (2010) Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 41:1794-1801
101. Yuanhong X, Feng X, Qingchang L, Jianpeng F, Zhe L, Kejian G (2010) Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers 25:136-140